Chinmay Shukla
Senior Vice President, Strategic Finance
Replay available
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call
BridgeBio Pharma, Inc. (NASDAQ: BBIO) Q2 2026 earnings conference call, held 2026-08-10. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Neil Kumar
Chief Executive Officer
Matt Outten
Chief Commercial Officer
Tom Trimarchi
President and Chief Financial Officer
Anant Sridhar
Program Lead, Incalorate (ADH1)
Christine Xu
Program Lead, BBP418 (LGMD2I)
Justin To
Program Lead, Infogratinib (Achondroplasia)
Tyler Van Buren
Analyst at TD Cowen
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Bridgebio Pharma, Inc..
Replay transcript excerpt
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a04134-5035-7061-81cf-7319623a5c91 Created: 2026-08-27T03:12:26.200Z Duration: 3762.9387 Channels: 1 00:00:00.320 -- 00:00:02.560 Good afternoon. I will be your conference operator 00:00:02.560 -- 00:00:04.880 today. All lines have been placed on mute 00:00:04.880 -- 00:00:07.759 to prevent any background noise. After the company's 00:00:07.759 -- 00:00:09.440 remarks, there will be a question and answer 00:00:09.440 -- 00:00:09.760 session. 00:00:18.895 -- 00:00:20.815 Before we begin, I would like to remind 00:00:20.815 -- 00:00:23.135 everyone that today's call may contain forward looking 00:00:23.135 -- 00:00:25.375 statements within the meaning of the federal securities 00:00:25.375 -- 00:00:26.095 laws, 00:00:26.255 -- 00:00:29.135 including, but not limited to, statements about BridgeBio's 00:00:29.135 -- 00:00:31.660 future operating and financial performance, 00:00:31.980 -- 00:00:34.540 business plans and prospects and strategy. 00:00:35.020 -- 00:00:37.500 These statements are based on current expectations and 00:00:37.500 -- 00:00:40.300 assumptions that are subject to risks and uncertainties, 00:00:40.460 -- 00:00:42.860 which could cause actual results to differ materially 00:00:42.860 -- 00:00:45.475 from those expressed or implied in these forward 00:00:45.475 -- 00:00:46.435 looking statements. 00:00:46.835 -- 00:00:49.235 For a discussion of these risks and uncertainties, 00:00:49.235 -- 00:00:51.235 please refer to the disclosure in today's earnings 00:00:51.235 -- 00:00:52.595 release and BridgeBio's 00:00:52.595 -- 00:00:55.075 periodic reports and SEC filings. 00:00:55.635 -- 00:00:57.899 All statements made here are based on information 00:00:57.899 -- 00:01:00.699 available to Bridge...